Progenics Pharma (PGNX) Begins Phase 1 Trial of its PSMA-Targeted Therapeutic Candidate 1095 ForTreatment of Metastatic Prostate Cancer
Tweet Send to a Friend
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
